Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer

Journal of Biological Chemistry

Volumn 287, Issue 41, 2012, Pages 34019-34031

  Saraon, Punit ^a,b   Musrap, Natasha ^a,b   Cretu, Daniela ^a,b   Karagiannis, George S ^a,b   Batruch, Ihor ^a   Smith, Chris ^a   Drabovich, Andrei P ^a   Trudel, Dominique ^c   Van Der Kwast, Theodorus ^b,c   Morrissey, Colm ^d   Jarvi, Keith A ^a   Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION; ANDROGEN-DEPENDENT; CELL LINES; IMMUNOHISTOCHEMISTRY; INTEGRAL STEPS; PLASMA SAMPLES; PROSTATE CANCER CELLS; PROSTATE CANCERS; PROTEOMES; PROTEOMIC PROFILING; QUANTITATIVE PCR; THERAPEUTIC INTERVENTION; TISSUE EXPRESSION;

CELL CULTURE; CELLS; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PROTEINS; TISSUE; UROLOGY;

DISEASES;

ANDROGEN; PROTEIN S; PROTEOME;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEOMICS; QUANTITATIVE ANALYSIS; SEMINAL PLASMA;

ANDROGENS; BLOOD PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867257723     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.384438     Document Type: Article

References (48)

1. Grönberg, H. (2003) Prostate cancer epidemiology. Lancet 361, 859-864
2. Diamandis, E. P. (1998) Prostate-specific antigen. Its usefulness in clinical medicine. Trends Endocrinol. Metab. 9, 310-316
3. Sardana, G., Dowell, B., and Diamandis, E. P. (2008) Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin. Chem. 54, 1951-1960 (Pubitemid 352774027)
4. Denmeade, S. R., and Isaacs, J. T. (2002) A history of prostate cancer treatment. Nat. Rev. Cancer 2, 389-396 (Pubitemid 37328952)
5. Saraon, P., Jarvi, K., and Diamandis, E. P. (2011) Molecular alterations during progression of prostate cancer to androgen independence. Clin. Chem. 57, 1366-1375
6. Chodak, G. W., Kranc, D. M., Puy, L. A., Takeda, H., Johnson, K., and Chang, C. (1992) Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J. Urol. 147, 798-803
7. Crawford, E. D., and Petrylak, D. (2010) Castration-resistant prostate cancer. Descriptive yet pejorative? J. Clin. Oncol. 28, e408
8. Debes, J. D., and Tindall, D. J. (2004) Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488-1490 (Pubitemid 39315314)
9. Ruizeveld de Winter, J. A., Trapman, J., Vermey, M., Mulder, E., Zegers, N. D., and van der Kwast, T. H. (1991) Androgen receptor expression in human tissues. An immunohistochemical study. J. Histochem. Cytochem. 39, 927-936
10. Sadi, M. V., Walsh, P. C., and Barrack, E. R. (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67, 3057-3064
11. Edwards, J., and Bartlett, J. M. (2005) The androgen receptor and signal transduction pathways in hormone-refractory prostate cancer. Part 1. Modifications to the androgen receptor. BJU Int. 95, 1320-1326 (Pubitemid 40799454)
12. Edwards, J., and Bartlett, J. M. (2005) The androgen receptor and signal transduction pathways in hormone-refractory prostate cancer. Part 2. Androgen receptor cofactors and bypass pathways. BJU Int. 95, 1327-1335 (Pubitemid 40799455)
13. Karagiannis, G. S., Pavlou, M. P., and Diamandis, E. P. (2010) Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol 4, 496-510
14. Alaiya, A. A., Al-Mohanna, M., Aslam, M., Shinwari, Z., Al-Mansouri, L., Al-Rodayan, M., Al-Eid, M., Ahmad, I., Hanash, K., Tulbah, A., Bin Mahfooz, A., and Adra, C. (2011) Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int. J. Oncol. 38, 1047-1057
15. Khan, A. P., Poisson, L. M., Bhat, V. B., Fermin, D., Zhao, R., Kalyana-Sundaram, S., Michailidis, G., Nesvizhskii, A. I., Omenn, G. S., Chinnaiyan, A. M., and Sreekumar, A. (2010) Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9, 298-312
16. Sardana, G., Jung, K., Stephan, C., and Diamandis, E. P. (2008) Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines. Discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 7, 3329-3338
17. Skvortsov, S., Schäfer, G., Stasyk, T., Fuchsberger, C., Bonn, G. K., Bartsch, G., Klocker, H., and Huber, L. A. (2011) Proteomics profiling of microdissected low and high grade prostate tumors identifies LaminAas a discriminatory biomarker. J. Proteome Res. 10, 259-268
18. Tyson, D. R., and Ornstein, D. K. (2008) Proteomics of cancer of hormone-dependent tissues. Adv. Exp. Med. Biol. 630, 133-147
19. Vellaichamy, A., Dezso, Z., JeBailey, L., Chinnaiyan, A. M., Sreekumar, A., Nesvizhskii, A. I., Omenn, G. S., and Bugrim, A. (2010) "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 5, e10936
20. Zheng, Y., Xu, Y., Ye, B., Lei, J., Weinstein, M. H., O'Leary, M. P., Richie, J. P., Mok, S. C., and Liu, B. C. (2003) Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98, 2576-2582 (Pubitemid 37509520)
21. Drake, R. R., Elschenbroich, S., Lopez-Perez, O., Kim, Y., Ignatchenko, V., Ignatchenko, A., Nyalwidhe, J. O., Basu, G., Wilkins, C. E., Gjurich, B., Lance, R. S., Semmes, O. J., Medin, J. A., and Kislinger, T. (2010) In depth proteomic analyses of direct expressed prostatic secretions. J. Proteome Res. 9, 2109-2116
22. Tsui, K. H., Chang, P. L., Feng, T. H., Chung, L. C., Sung, H. C., and Juang, H. H. (2008) Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res. 28, 1993-1999
23. Trendel, J. A., Ellis, N., Sarver, J. G., Klis, W. A., Dhananjeyan, M., Bykowski, C. A., Reese, M. D., and Erhardt, P. W. (2008) Catalytically active peptidylglycine α-amidating monooxygenase in the media of androgen-independent prostate cancer cell lines. J. Biomol. Screen. 13, 804-809
24. 1 arrest in prostate cancer cells. Int. J. Cancer 130, 200-212
25. Latil, A., Chêne, L., Cochant-Priollet, B., Mangin, P., Fournier, G., Berthon, P., and Cussenot, O. (2003) Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103, 306-315 (Pubitemid 36076423)
26. Jarvis, G. A., Li, J., Hakulinen, J., Brady, K. A., Nordling, S., Dahiya, R., and Meri, S. (1997) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int. J. Cancer 71, 1049-1055 (Pubitemid 27252889)
27. Cao, J., Chiarelli, C., Richman, O., Zarrabi, K., Kozarekar, P., and Zucker, S. (2008) Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J. Biol. Chem. 283, 6232-6240
28. Damon, S. E., Maddison, L., Ware, J. L., and Plymate, S. R. (1998) Overexpression of an inhibitory insulin-like growth factor-binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 139, 3456-3464 (Pubitemid 28512302)
29. Jennbacken, K., Tesan, T., Wang, W., Gustavsson, H., Damber, J. E., and Welén, K. (2010) N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 17, 469-479
30. Blanchère, M., Mestayer, C., Saunier, E., Broshuis, M., and Mowszowicz, I. (2001) Transforming growth factor β in the human prostate. Its role in stromal-epithelial interactions in non-cancerous cell culture. Prostate 46, 311-318 (Pubitemid 32186914)
31. Wolff, J. M., Stephenson, R. N., Chisholm, G. D., and Habib, F. K. (1995) Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur. J. Cancer 31A, 339-341
32. Taddei, M. L., Parri, M., Angelucci, A., Onnis, B., Bianchini, F., Giannoni, E., Raugei, G., Calorini, L., Rucci, N., Teti, A., Bologna, M., and Chiarugi, P. (2009) Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am. J. Pathol. 174, 1492-1503
33. Miyake, H., Pollak, M., and Gleave, M. E. (2000) Castration-induced upregulation of insulin-like growth factor-binding protein-5 potentiates in-sulin- like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 60, 3058-3064 (Pubitemid 30395835)
34. Suh, J., and Rabson, A. B. (2004) NF-κB activation in human prostate cancer. Important mediator or epiphenomenon? J. Cell. Biochem. 91, 100-117
35. Blando, J. M., Carbajal, S., Abel, E., Beltran, L., Conti, C., Fischer, S., and DiGiovanni, J. (2011) Cooperation between Stat3 and Akt signaling leads to prostate tumor development in transgenic mice. Neoplasia 13, 254-265
36. Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., and Abate-Shen, C. (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118, 3051-3064
37. MAPK-dependent activation of mTOR and cyclin D1 expression in prostate and lung cancer cells. Int. J. Biochem. Cell Biol. 41, 603-614
38. Zhang, F., Lee, J., Lu, S., Pettaway, C. A., and Dong, Z. (2005) Blockade of transforming growth factor-β signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin. Cancer Res. 11, 4512-4520 (Pubitemid 40825642)
39. Davis, J. S., Nastiuk, K. L., and Krolewski, J. J. (2011) TNF is necessary for castration-induced prostate regression, whereas TRAIL and FasL are dispensable. Mol. Endocrinol. 25, 611-620
40. Sierko, E., Wojtukiewicz, M. Z., Zawadzki, R., Zimnoch, L., and Kisiel, W. (2010) Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer. Thromb. Res. 125, e71-e5
41. Hafizi, S., and Dahlbäck, B. (2006) Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273, 5231-5244 (Pubitemid 44772384)
42. Hafizi, S., and Dahlbäck, B. (2006) Signaling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 17, 295-304 (Pubitemid 44038616)
43. Hall, M. O., Obin, M. S., Heeb, M. J., Burgess, B. L., and Abrams, T. A. (2005) Both protein S and Gas6 stimulate outer segment phagocytosis by cultured rat retinal pigment epithelial cells. Exp. Eye Res. 81, 581-591 (Pubitemid 41532003)
44. Lemke, G., and Rothlin, C. V. (2008) Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8, 327-336 (Pubitemid 351595219)
45. Sainaghi, P. P., Castello, L., Bergamasco, L., Galletti, M., Bellosta, P., and Avanzi, G. C. (2005) Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J. Cell. Physiol. 204, 36-44 (Pubitemid 40776804)
46. Shiozawa, Y., Pedersen, E. A., Patel, L. R., Ziegler, A. M., Havens, A. M., Jung, Y., Wang, J., Zalucha, S., Loberg, R. D., Pienta, K. J., and Taichman, R. S. (2010) GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127
47. Guo, H., Barrett, T. M., Zhong, Z., Fernández, J. A., Griffin, J. H., Freeman, R. S., and Zlokovic, B. V. (2011) Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol. Neurodegener. 6, 13
48. Zhong, Z., Wang, Y., Guo, H., Sagare, A., Fernández, J. A., Bell, R. D., Barrett, T. M., Griffin, J. H., Freeman, R. S., and Zlokovic, B. V. (2010) Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J. Neurosci. 30, 15521-15534